Heraeus Medical, the Global Business Unit of German technology group Heraeus, signed a cooperation with the Korean company Kang Stem Biotech to develop a treatment for degenerative arthritis. As part of the cooperation Heraeus Medical and Kang Stem Biotech will take the development program through pre-clinical studies and to phase 1/2a clinical trials.
Both companies share the common goal to develop a therapeutic agent for degenerative arthritis with superior effects than existing treatment approaches. The therapy will be based on expanded umbilical cord blood-derived mesenchymal stem cells. Kang Stem is ranked number 3 worldwide for Stem Cell-related patents holdings and has 80 employees with an own Stem Cell GMP centre and research institute.
“We are pleased to partner with Kang Stem Biotech to be able to accelerate the progress of this exciting technology into the treatment of arthritis,” says Andrew Williamson of Heraeus Medical. “We believe that the market for new solutions is rapidly growing due to an aging population and advancing Asian markets that are in need of superior medical treatments.”